Myeloproliferative Neoplasm Quality Of Life (MPN-QOL) Study Group: Observational Study Of Quality Of Life and Symptomatic Response In Myelofibrosis Patients Receiving Undergoing Treatment With Conventional Therapy, The Measures Trial and Allogeneic Stem Cell Transplant, The Symptoms Trial

Veena Fauble(Mayo Clinic in Arizona), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Gunnar Birgegård(Uppsala University Hospital), Aaron T. Gerds(Cleveland Clinic), Deepti Radia(St Thomas' Hospital), Constantine S. Tam(The Alfred Hospital), Emily Knight(Mayo Clinic in Arizona), David M. Ross(Flinders Medical Centre), Björn Andréasson(NU Hospital Group), Federico Sackmann(Centre Hospitalier Universitaire de Grenoble), Holly L. Geyer(Mayo Clinic Hospital), Jan Michiels(VIB-KU Leuven Center for Microbiology), Uday Popat(The University of Texas MD Anderson Cancer Center), Vikas Gupta(Indian Institute of Technology Kanpur), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Bart L. Scott(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Christen Lykkegaard Andersen(Copenhagen University Hospital), Robyn M. Emanuel(Centre Hospitalier Universitaire de Grenoble), Michael Boxer(Arizona Oncology), Amylou C. Dueck(Mayo Clinic in Arizona), Peter Johansson(Sahlgrenska University Hospital), Jean‐Loup Demory(Centre Hospitalier Universitaire de Lille), Nicolaus Kröger(Universität Hamburg), Ana Kerguelen Fuentes(Centre Hospitalier Universitaire de Grenoble), Elisabeth Ejerblad(Uppsala University)
Blood
November 15, 2013
Cited by 2


Related Papers